An in vitro or ex vivo method for detection or prognosis of lung cancer in a subject, by determination of the qualitative and quantitative variation of the antigenic epitome associated with LC, the method comprising: a) contacting a sample from said subject, preferably a blood plasma sample, with at least five antibodies wherein - the first antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 14 to 16, - the second antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 34 to 48, - the third antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 72 to 77, - the fourth antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 109 to 114, and - the fifth antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 142 to 147, or one fragment or derivative of such antibodies having the same antigen specificity, b) determining the presence or the absence and the level of binding of at least the epitope-antigens of each group of sequences with said at least five antibodies, forming antibody/epitope-antigen complexes, c) comparing the test results of the determination in step (b) to a control, whereby LC is to be detected / diagnosed / predicted, said presence or absence of the epitope-antigen complexes with said at least five antibodies being indicative of LC. a) contacting a sample from said subject, preferably a blood plasma sample, with at least five antibodies wherein - the first antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 14 to 16, - the second antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 34 to 48, - the third antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 72 to 77, - the fourth antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 109 to 114, and - the fifth antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 142 to 147, or one fragment or derivative of such antibodies having the same antigen specificity, - the first antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 14 to 16, - the second antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 34 to 48, - the third antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 72 to 77, - the fourth antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 109 to 114, and - the fifth antibody specifically binds at least one epitope-antigen comprising or consisting of the sequences selected from the group consisting of SEQ ID NO: 142 to 147, b) determining the presence or the absence and the level of binding of at least the epitope-antigens of each group of sequences with said at least five antibodies, forming antibody/epitope-antigen complexes, c) comparing the test results of the determination in step (b) to a control, whereby LC is to be detected / diagnosed / predicted, said presence or absence of the epitope-antigen complexes with said at least five antibodies being indicative of LC.